These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35978180)

  • 1. Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia.
    Santaliestra M; Ferrer-Marín F; Alvarez-Larrán A;
    Ann Hematol; 2022 Nov; 101(11):2563-2564. PubMed ID: 35978180
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.
    Jurgens DJ; Moreno-Aspitia A; Tefferi A
    Haematologica; 2004 Nov; 89(11):1394-5. PubMed ID: 15531464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
    Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term use of anagrelide in young patients with essential thrombocythemia.
    Storen EC; Tefferi A
    Blood; 2001 Feb; 97(4):863-6. PubMed ID: 11159509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
    Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
    Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When and how to treat essential thrombocythemia.
    Barbui T; Finazzi G
    N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
    [No Abstract]   [Full Text] [Related]  

  • 8. Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia.
    Swords R; Fay M; O'Donnell R; Murphy PT
    Eur J Haematol; 2004 Sep; 73(3):223-4. PubMed ID: 15287922
    [No Abstract]   [Full Text] [Related]  

  • 9. Is anagrelide safe during pregnancy?
    Cornet N; Vialard F; Mir O; Berveiller P
    J Gynecol Obstet Hum Reprod; 2017 Nov; 46(9):697-699. PubMed ID: 28866127
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of starting doses of anagrelide as a first-line therapy in patients with cytoreductive therapy-naïve essential thrombocythemia: difference between starting at 0.5 and 1.0 mg/day.
    Hashimoto Y; Ito T; Tanaka Y; Nakaya A; Fujita S; Satake A; Nakanishi T; Konishi A; Hotta M; Yoshimura H; Ishii K; Hashimoto A; Kondo T; Omura H; Shinzato I; Tanaka T; Nomura S
    Int J Hematol; 2020 Jul; 112(1):33-40. PubMed ID: 32328973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
    Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute coronary syndromes and Anagrelide.
    Lin GM; Chao TY; Wang WB
    Int J Cardiol; 2007 Apr; 117(1):e17-9. PubMed ID: 17320215
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
    Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
    Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for lowering platelet numbers in essential thrombocythemia.
    Barbui T
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):22-5. PubMed ID: 12682878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
    Rey J; Viallard JF; Keddad K; Smith J; Wilde P; Kiladjian JJ;
    Eur J Haematol; 2014 Feb; 92(2):127-36. PubMed ID: 24118452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia.
    Kayrak M; Acar K; Yazici M; Kaya C; Ayhan SS; Gok H
    Clin Appl Thromb Hemost; 2009; 15(4):465-6. PubMed ID: 18160579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
    Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
    Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Samuelson B; Chai-Adisaksopha C; Garcia D
    J Thromb Thrombolysis; 2015 Nov; 40(4):474-9. PubMed ID: 25894476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.